Indications for peripheral, midline and central catheters: summary of the MAGIC recommendations

Nancy Moureau and Vineet Chopra

Intravenous access is a necessary component of the delivery of medical treatment in hospitals. More than 60% of patients in acute care worldwide, and higher percentages in the USA, require a vascular access device (VAD) (Alexandrou, 2015). Central venous access devices (CVADs) exceed 7 million units per year in the USA and 10 million worldwide (iData Research, 2014), and while necessary in most cases, each CVAD carries significant risk to the patient (Napalkov et al, 2013; Chopra et al, 2012a; 2012b). Recent concerns over serious complications of infection and thrombosis require closer scrutiny of CVAD use with particular emphasis on applying evidence-based indications and avoiding potential overuse of peripherally inserted central catheters (PICCs) (Maki et al, 2006; Chopra et al, 2012b; 2013a; 2013b; 2014; Hammes et al, 2015; Carr and Rippey, 2015). Due to increasing popularity, ease of insertion, low insertion related complications, reduced cost and placement primarily by vascular access teams, PICCs now comprise nearly half of all CVADs currently used in the USA (iData Research, 2014). Despite the advantages and safety in terms of insertion, PICCs are prone to occlusion and venous thrombosis, by a factor of more than 2 in comparison with other CVADs (Moureau et al, 2002; Spencer et al, 2007; Evans et al, 2010; Saber et al, 2011; Marnejon et al, 2012; Chopra et al, 2013a; Evans et al, 2013). PICC venous thrombosis is known to also impact the risk of lower-extremity thrombosis and potentially contribute to incidence of pulmonary emboli (Greene et al, 2015; Kaplan et al, 2015). Selecting the intravenous device with the lowest risk that most effectively supports the patient’s treatment plan should be performed based on available evidence and specified indications.

Method
Recognising the need to establish evidence-based indications for intravascular devices and specifically PICCs, an international group of expert physicians, clinicians and one patient was selected to work together as part of a University of Michigan/Society of Hospital Medicine-funded initiative. In this initiative, the RAND/UCLA Appropriateness Method (Fitch et al, 2001) was applied to develop criteria for the selection of the best VAD for each patient. A systematic literature review was performed and disseminated to the 15-member panel for evaluation with the 665 patient scenarios. To determine the effect on clinical decision-making, devices including peripheral intravenous catheters, ultrasound-guided peripheral intravenous catheters, midline catheters, non-tunelled central venous catheters (CVCs), tunnelled CVCs, and ports, were compared with PICCs. Additionally, scenarios evaluating the appropriateness of individual devices were also created. Each scenario was rated based on appropriateness of PICC or other VAD usage. The RAND/UCLA Appropriateness Method incorporated information synthesis, panelist selection, patient scenarios, a rating process and analysis of results all specific to VADs.
Peripheral access (PIV, USGPIV)

Peripheral catheters establish access into the veins and arteries of the arms and, less frequently, legs or other paediatric or neonatal applications of the scalp (Rickard et al, 2012; McCay, 2014). They are inserted using a direct visual approach or with visualisation devices such as infra-red or ultrasound technology. Peripheral access is considered less invasive than central access and has a lower risk of infection (0.5/1000 catheter days) (Maki et al, 2006; Hadaway, 2012). Peripheral catheters are considered appropriate for treatment of peripherally compatible medications and solutions (less than 900 mOsm/litre, not vesicant or irritant) when the duration of treatment is 6 days or less (Table 1) with transition to midline or PICC when duration is extended (Periard et al, 2008; Gorski et al, 2016).

When multiple peripheral catheter attempts fail, the designation of difficult intravenous access (DIVA) may lead to assessment and access with ultrasound or other forms of visualisation technology (Figure 1). Success is enhanced with deeper ultrasound-guided access and the use of longer peripheral catheters (Chinnock et al, 2007; Elia et al, 2012; Liu et al, 2014; Stolz et al, 2015). For all patients considered DIVAs, those with one or more failed attempts, inability to identify veins visually or with a history of difficult access, use of ultrasound or other visual technologies is recommended to help obtain the preferred peripheral intravenous access (Gorski et al, 2016). Ultrasound-guided peripheral access (USGPIV), commonly inserted in the veins of the forearm, antecubital fossa or upper arm, is indicated for treatment duration less than 6 days or up to 15 days with a transition to midline catheter or PICC if treatment continues. USGPIV is also recommended for contrast-based radiographic studies requiring upper-extremity veins with larger catheters, 20–16 gauge, where visible veins to accommodate the size are not available (Table 2). Evidence supports greater success with ultrasound-guided peripheral catheter access after training (Schoenfeld et al, 2011). Greater success with these procedures results in reduced need and avoidance of CVADs (Gregg et al, 2010; Au et al, 2012; Shokoochi et al, 2013).

Current research and guidelines support maintaining peripheral catheters until no longer clinically indicated or until a complication develops (Rickard et al, 2012; Gorski et al, 2012; Loveday et al, 2014; Tuffaha et al, 2014; Wallis et al, 2014; Bolton, 2015). Insertion of peripheral catheters into external jugular or leg veins is considered appropriate in emergent situations with verified inserter training prior to the insertion and treatment is 4 days or less (Chopra et al, 2015a). Peripheral catheters in the hand or distal portion of the upper extremity are the preferred choice when chronic kidney disease (CKD) is present and glomerular filtration rate (GFR) is less than 44 ml/minute, stage 3b or greater, with a focus on preserving peripheral and central veins for haemodialysis, fistula or grafts (Chopra et al, 2015a).

Peripheral catheters are the preferred access for all patients where no indication is present for central venous access (Chopra et al, 2015a). Increasing clinical skill with vein selection and access through the use of ultrasound and other visual aids facilitates the goal of avoiding CVADs when no indication

### Table 1. Peripheral catheter indications

- Peripheral intravenous catheter treatment involves the infusion of peripherally compatible solutions for 5 days or less
- Patient has adequate veins to accommodate catheter size and length
- Emergent use with placement in the external jugular or foot veins (emergent or less than 4 days)
- Cyclic or episodic chemotherapy (non-vesicant) treatment for less than 3 months

### Table 2. Ultrasound-guided peripheral catheter indications

- Use visualisation technology to establish peripheral access using longer catheters for the purpose of intravenous treatment less than 5 days or more than 15 days (with transition to midline or PICC)
- For patients with one or more failed attempts, inability to identify veins visually or those identified as difficult intravenous access (DIVA) commonly inserted in the forearm, antecubital fossa or upper arm
- For contrast based radiological studies requiring upper extremity access in larger veins with 20-, 18- or 16-gauge catheter (where visible veins to accommodate catheter size are not present)

### Table 3. Midline catheter indications

- Treatment involves peripherally appropriate solutions that will likely exceed 6 days
- Preferred for patients requiring infusions of up to 14 days
- Patients with difficult intravenous access (DIVA) despite ultrasound-guided peripheral catheter attempts
- Single-lumen midline is placed unless specific indication for dual lumen with compatible infusions

Figure 1. Ultrasound-guided peripheral catheter in the forearm (used with permission from PICC Excellence, Inc.)

Results

The results of the review by the Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) panel included ratings from 391 unique indications of appropriateness or inappropriateness for PICCs and other VADs with two rounds of in-person rating scenarios by the panel (Chopra et al, 2015a). The final results established 38% of these indications as appropriate, 43% as inappropriate and 19% neutral or uncertain for the 665 scenarios. Details for each device are summarised in the following sections.
exists for these devices. Many hospitals have incorporated vascular access teams to insert and maintain both peripheral and central catheters with positive outcomes (Hawes, 2007). The added expertise and skill of these team members supports the longer use of peripheral catheters.

Midline catheters

Midline catheters are experiencing a resurgence of attention with great usage owing to improvements in catheter materials and products. The two most recent midline catheters are 8–10 cm in length utilising the insertion technique referred to as accelerated Seldinger (AST) (Access Scientific, Bard Access Systems, Teleflex). These all-in-one devices with the modified Seldinger technique (MST) have the needle, wire and introducer in a combined unit for ease and speed in access. The evidence supporting midlines is growing with a variety of publications demonstrating positive outcomes (Anderson et al, 2004; Griffiths, 2007; Alexandrou et al, 2011; Cummings et al, 2011; Warrington et al, 2012; Dawson and Moureau, 2013; Caparas and Hu, 2014; Moureau et al, 2015).

Midline catheters have lower phlebitis rates than peripheral catheters and lower rates of infection than other central catheters. Midlines are considered appropriate for patients with peripherally compatible solutions or medications where treatment will likely exceed 6 days. Midlines are preferred for patients requiring infusions up to 14 days, but may be used in a manner consistent with the clinically indicated removal of peripheral catheters (O’Grady et al, 2011; Caparas and Hu, 2014) (Table 3). When patients are considered DIVAs and ultrasound-guided peripheral access has failed, midlines are preferred (Figure 2). As with all vascular access devices, single lumen midline catheters are placed unless a specific indication for additional lumen. Use smaller gauge PICC with fewer lumen to reduce risk of deep vein thrombosis (DVT) (Grove and Pevec, 2000; Evans et al, 2013). Measure vein size to establish appropriate catheter size of less than 45% of vein diameter (Sharp et al, 2015). Position of terminal tip of PICC in lower third of the superior vena cava, cavoatrial junction or right atrium.

### Table 4. PICC indications

- Patient requires intravenous access for longer than 14 days. For proposed treatment of 6 or more days ultrasound-guided or midline catheter preferred over PICC
- Clinically stable patient requiring intravenous therapy with peripherally incompatible solutions. Haemodynamically unstable patients where cardiac monitoring or use of vasopressors is necessary in cases less than 14 days and more than 15 days (CVCs favoured over PICCs)
- PICC is preferred to CVAD for critically ill patients with bleeding disorders for 14 days or less and those requiring 15 or more days of treatment
- For use with continuous infusions of vesicant, parenteral nutrition, chemically irritating or non-peripherally compatible solutions for any duration. For cyclic chemotherapy with active cancer where treatment is more than 3 months. Consideration given to discontinuation of PICC when each cycle complete (peripheral catheter preferred when less than 3 months)
- Use with patients receiving frequent phlebotomy of every 8 hours or more often with duration of 6 days or more
- For burn patients where early implementation of PICC decreases risk of bacteraemia
- For use with chronic or lifelong access populations (sickle cell, cystic fibrosis, short gut) or those hospitalised more frequently than 6 times per year (tunneled catheter preferred)
- For use in patients in palliative treatment, actively dying or in hospice requiring intravenous solutions
- For skilled nursing facilities when duration of treatment is more than 14 days
- Prior nephrology approval if glomerular filtration rate (GFR) less than 30 or creatinine more than 2.0
- Single-lumen PICCs preferred unless specific indication for additional lumen. Use smaller gauge PICC with fewer lumen to reduce risk of deep vein thrombosis (DVT) (Grove and Pevec, 2000; Evans et al, 2013). Measure vein size to establish appropriate catheter size of less than 45% of vein diameter (Sharp et al, 2015). Position of terminal tip of PICC in lower third of the superior vena cava, cavoatrial junction or right atrium

**Peripherally inserted central catheters (PICC)**

PICCs have provided a reliable bridge between shorter peripheral catheters and chest-inserted central venous catheters (CICC) for more than 20 years (Figure 3). There is reduced risk of pneumothorax, haemothorax, nerve damage, stenosis and other...
Patients requiring intermittent or cyclic infusion treatment, rather than continuous, for treatment longer than 6 months (neutral rating for 3–6 month duration of treatment). Infusions of vesicant, irritant, parenteral nutrition or chemotherapeutic agents are often used for these critical patients, to reduce the risk of infection by approximately 40%, to 14 days. For renal failure stage 3b or greater chronic kidney disease with GFR of less than 44 ml/minute or for patients currently receiving any renal replacement therapy.

### Table 6. Non-tunnelled catheter indications

- Unstable patients requiring haemodynamic monitoring, multiple medications, large fluid infusions, blood or blood products or continuous parenteral nutrition
- Short-term critical access. Non-tunnelled CVCs are preferred over PICCs for access up to 14 days
- Chemotherapy treatment anticipated for more than 3 months
- Antimicrobial non-tunnelled catheters are often used for these critical patients to reduce the risk of infection by approximately 40%.

### Table 7. Tunneled catheter indications

- Patients receiving treatment exceeding 31 days
- Infusion of vesicant, irritant, parental nutrition or chemotherapeutic agents regardless of duration
- Patients likely to receive cyclic or intermittent ongoing therapy exceeding 31 days
- Patients with more than 6 hospitalisations annually with expected duration of therapy longer than 15 days per hospitalisation.

### Table 8. Totally implanted subcutaneous port indications

- Patients with expected treatment longer than 6 months (neutral rating for 3–6 month duration of treatment)
- Patients requiring intermittent or cyclic infusion treatment, rather than continuous, for more than 6 months.

more serious CVAD-related complications with PICC placement. Indications for PICCs (Table 4) include any patient requiring peripherally incompatible infusions or for intravenous treatment more than 14 days (Chopra et al, 2015a). Expanded nursing roles support safe placement of PICCs by specially trained teams of nurses (Robinson et al, 2005; Falkowski, 2006; Simcock, 2008). Increased awareness of PICCs has reduced the number of other CVAD placements. Bedside nurses are more likely to request a PICC order after having difficulty establishing peripheral access rather than considering all options and appropriateness of central access (Chopra et al, 2015b; Helm et al, 2015; Woller et al, 2015).

With rising concerns over the incidence of thrombosis with PICCs and the relationship of thrombosis to infection, closer evaluation of each PICC request is necessary to evaluate the need for central versus peripheral access for each patient (Marshall et al, 2014; Chopra et al, 2015a). Measuring the vein diameter and choosing a catheter–to–vein ratio of 45% or less may reduce thrombosis risk in PICCs and midlines (Nifong and McDevitt, 2011; Sharp et al, 2015; Gorski et al, 2016). Use of antimicrobial PICCs may reduce risk and was statistically significant in reducing the level of infection by a factor of 4 in one hospital study (Rutkoff, 2014). In Tables 4 and 5 a list of appropriate and inappropriate indications for PICCs is provided based on MAGIC (Chopra et al, 2015a).

### Non-tunnelled central venous catheters

Non-tunnelled CVCs are commonly used for internal jugular access with acute care patients who are unstable and who require haemodynamic monitoring or large fluid infusions. These percutaneously inserted catheters have a rate of infection similar to PICCs (Maki et al, 2006) and are used for short-term critical access. Non-tunnelled CVCs are preferred over PICCs when treatment is required for 14 days or less. Antimicrobial non-tunnelled catheters are often used for these critical patients when the catheter is expected to stay in place for more than 5 days to reduce risk of infection (Hockenhull et al, 2008; Pittiruti et al, 2009; Lai et al, 2013; Chopra et al, 2015a; Lorente et al, 2016) (Table 6).

### Tunnelled central venous catheters

Tunnelled CVCs are inserted into internal jugular or subclavian veins with a subcutaneous tunnel commonly to the mid-chest region, but also other areas customised to the patient. Tunnelled catheters are indicated for use with intravenous treatment of 31 days or longer, or more episodic treatment over several months. Typically, these CVADs are reserved for patients not considered candidates for a PICC due to vein size or thrombosis risk. Tunnelled internal jugular catheters and small bore catheters are preferred for patients with any level of CKD requiring intravenous treatment for more than 15 days. PICC and tunneled catheters are appropriate at all time intervals for infusion of irritating or chemotherapeutic medications. Tunnelled catheters are recommended over multilumen PICCs when multiple or frequent infusions are required due to their lower incidence of complications (Tran et al, 2010; Chopra et al, 2015a) (Table 7).

### Subcutaneously implanted ports

With subcutaneously implanted ports, a catheter is inserted into either the internal jugular or subclavian vein and attached to a port reservoir. The port is implanted into a pocket created in a subcutaneous area on the chest (or arm as in arm ports), connected to the catheter, tested for flow and secured with sutures or glue (Simonova et al, 2012; Chopra et al, 2015a). Ports are appropriate for patients with expected treatment longer than 6 months. The MAGIC panelists rated ports as having neutral appropriateness for duration of treatment equal to 3–6 months. Ports may also be considered appropriate for difficult venous access if use for 31 days or more is expected (Chopra et al, 2015a) (Table 8).
Discussion

For the first time, the MAGIC document provides appropriateness ratings for specific VADs based on infusate, patient, duration and treatment characteristics. Factors such as proposed duration of medication infusions, effects of the medication on vessels, patient condition (renal, critical, chronic) or complications of infection were all evaluated (Figure 4), helping create clinically practical recommendations. However, recommendations for clinical appropriateness are often based on criteria that are difficult to estimate, such as duration of treatment. As emphasised by the patient panelist in the MAGIC initiative, an individualised approach is necessary in many situations.

Application of the appropriateness criteria may also require adaptation to the particular care setting (hospital, skilled nursing, home environment). Factors such as reliability of the VAD are more important in the skilled nursing and home environment where clinical support and expertise may be limited. Peripheral catheters and midlines have variable reliability outside the hospital setting.

The concept of vessel health and preservation is focused not just on gaining better outcomes during a single hospitalisation, but on preserving veins for future patient needs (Moureau et al, 2012; Hallam et al, 2016). Understanding and applying clinical research indicating the treatment, practice or process leading to the best results for the patient is challenging for clinicians. Selection of recommendations and guidelines is often convenience and economically oriented rather than patient focused, leading to a greater risk of complications for the patient.

It is important to remember that limitations exist for the MAGIC guidance. First, not all recommendations translate to all patient populations. For instance, placement of CVCs in critically ill patients requires the availability of experienced and skilled staff to insert devices in manners that are safe from insertion complications such as pneumothorax. This is implicitly assumed in MAGIC, but may not be so in the real world. Second, MAGIC does not address certain technological advances including antimicrobial-coated catheters or advanced devices such as infra-red vein finders that may impact on choice and selection of device. These limitations must be borne in mind when considering MAGIC. Technology ever advances and MAGIC should thus not be viewed as an all-encompassing document, but a living and breathing statement that changes with available evidence and practice. Third, it is unclear how best to implement recommendations from MAGIC. Should these be incorporated into checklists, software-based applications or electronic-medical record systems? Who is responsible for adherence? Are there potential barriers in implementation that have not been considered? These types of challenges require careful thought and the use of implementation science to better understand what works and what does not in the real-world setting.

MAGIC has succeeded in creating a practical list of indications, both appropriate and inappropriate, for VAD use. This document guides physicians, bedside clinicians, and those on vascular access teams to the most appropriate selection of the safest device and practices for the patient. To quote Thomas Vesely, a fellow clinician and designated Doctor of Medicine, who spoke to the authors:

‘More than 20 nationally-recognised guidelines, recommendations, and standards documents concerning vascular access were created by 10 different organisations. Insular creation of such documents is the wrong approach. It’s time that all involved agree on ‘the rules’ even if that requires compromise and MAGIC is a good step in the right direction.’

More expert discussion, evaluation and research is needed on issues where panelists failed to reach a decision, were neutral or disagreed for VAD indications. Consistent with the variation in panelist responses, published literature often has contradictions in results from one study to another. There was a paucity of randomised controlled trials for specific VADs necessary to establish definitive conclusions. Furthermore, what works in
one setting may not work in another. Understanding how best to implement MAGIC to improve decision-making in vascular access remains a key goal—one that must be actively targeted by those in this field.

Conclusion

Guidelines, recommendations and standards point to the need for evidence-based indications when selecting a VAD. Relying on available literature, the combined clinical experience of the panelists, patient input, and an established methodology embodied in the RAND/UCLA Method, a consensus was reached through MAGIC to establish a working guide for intravenous device indications and contraindications. Careful evaluation and application of MAGIC conclusions into the programme of each facility administering intravenous treatments provides guidance toward the most appropriate and safe patient applications. In this age of electronic medical records, criteria such as MAGIC may serve as a clinical decision process embedded in the electronic medical records framework to guide clinical decisions in keeping with the theory of vessel health and preservation for patients from birth to death.

BJN

Declaration of interest: none

This article is jointly published with The Journal of the Association for Vascular Access


Carr PJ, Rippey JCR (2015) Upper extremity deep vein thrombosis: a clinical decision process embodied in the electronic medical records framework to guide clinical decisions in keeping with the theory of vessel health and preservation for patients from birth to death. BJN

KEY POINTS

- The ability to preserve vessel health for future medical needs requires clinical education and training in three areas: device selection, placement and daily device care
- Selection of the most appropriate vascular access device (VAD) is necessary to avoid the potentially serious complications of infection and/or thrombosis.
- Selection of a central VAD (CVAD) should be based on indications for that specific device rather than the inability to gain peripheral access
- All VADs have a risk of infection and other complications for the patient and should be removed as soon as no longer medically necessary


Hockenhull JC, Dwan K, Boland A et al (2008) The clinical effectiveness and...


Have an idea for BJN?

☎️ 020 7738 5454 info@markallengroup.com © 2016 MA Healthcare Ltd

British Journal of Nursing, 2016, (IV Therapy Supplement) Vol 25, No 8